Table 4. Clinical and serologic findings of patients with primary Sjögren’s syndrome at time of diagnosis.

	n	%	Mean±SD	Min-Max
Symptom duration (year)			5.6±3.8	1-23
Xerostomia	72	67.3
Xerophthalmia	81	75.7
Vaginal dryness	19	17.8
Skin dryness	31	29.0
Joint complaint	100	93.5
Peripheral nervous system involvement	10	9.3
Central nervous system involvement	1	0.9
Pulmonary involvement	2	1.86
Renal involvement	2	1.86
Steroid usage	12	11.2
Sedimentation (mm/h)			36.9±1.9	5-91
C-reactive protein (mg/L)			8.4±1.1	0-59
Rheumatoid factor positivity	68	63.5
ANA positivity	101	94.4
Anti-Ro (SSA) positivity	68	63.5
Anti-Ro 52 positivity	70	65.4
Anti-La (SSB) positivity	41	38.3
Schirmer
Mild (10-15 mm/5 min)	20	18.7
Moderate (5-10 mm/5 min)	28	26.2
Advanced (<5 mm/5 min)	29	27.1
Focus score
0	11	10.3
1	37	34.5
2	32	29.9
3	22	20.5
SD: Standard deviation; Min: Minimum; Max: Maximum; ANA: Antinuclear antibody; Anti-Ro (SSA): Anti- Sjögren’s syndrome type A; Anti-La (SSB): Anti-Sjögren’s syndrome type B.